1. Scrip
  2. >>R&D

IIL-Griffith Univ Readying Reasonably Priced COVID-19 Vaccine

Vaccine Launch Expected In 18-24 Months

 
• By Vibha Ravi

The entry of India’s state-owned Indian Immunologicals and partner Griffith University in the COVID-19 vaccine race could potentially disrupt pricing dynamics. The alliance is developing a live-attenuated, single dose vaccine, which it hopes will be ready for launch in 18-24 months.

Independent
IIL-Griffith May Disrupt COVID-19 Vaccines Pricing • Source: Shutterstock

Indian Immunologicals Ltd has tied up with Australia’s Griffith University to develop a COVID-19 vaccine. While this by itself might not draw much attention given that nearly 60 vaccines are currently in the works to tackle the disease caused by the SARS-CoV-2 virus, the partnership’s capacity to disrupt potential pricing is noteworthy.

State-owned Indian Immunologicals Ltd (IIL) is one of India’s leading companies in human and veterinary biologicals and is known to undercut private-sector rivals, often quite sharply. For example, the paediatric pentavalent vaccine space saw a winning bid by IIL in a government-floated tender at INR29 ($0.38) per dose which was well below the INR49 a dose that the government had paid earlier

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.